

# Physiology of haemostasis

Abbas Zaidi

Laura Green

## Abstract

Haemostasis is a complex process that ensures the maintenance of blood flow under normal physiological conditions and prevents major blood loss following vascular injury. The process is tightly regulated to prevent pathological thrombosis. Normal haemostasis relies on the delicate balance of prothrombotic and anticoagulant processes, where five components play a significant role in maintaining the haemostasis, these include: (1) endothelial cells; (2) platelets which are key to platelet plug formation; (3) coagulation factors that are essential to formation of insoluble fibrin clot; (4) coagulation inhibitors; and (5) fibrinolysis. This article will provide an overview of the current concepts of haemostasis, and through this we will explain how antiplatelets and antithrombotic drugs work, as well as provide a basic understanding of how to interpret clotting tests used to measure coagulation disorders.

**Keywords** Anticoagulants; antiplatelets; bleeding; clotting tests; coagulation; haemorrhage; haemostasis; platelets

**Royal College of Anaesthetists CPD Matrix:** 1A01, 1A02

## Introduction

The haemostatic pathway is a tightly regulated process that ensures the maintenance of blood flow under normal physiological conditions and also facilitates the prevention of significant blood loss following vascular injury. The normal haemostatic response depends on the closely linked interaction between blood vessel wall (endothelial cells) platelets and blood coagulation factors. While an efficient and rapid mechanism for stopping bleeding is essential for survival, it is equally important that this mechanism is tightly controlled, so that pathological thrombosis is prevented. Therefore, normal haemostasis relies on the delicate balance of prothrombotic and anticoagulant processes.

There are five components of haemostasis

- blood vessels and endothelial cells
- platelets
- coagulation factors
- coagulation inhibitors
- clot dissolution or fibrinolysis.

This article will provide an overview of the current concepts of haemostasis, and through this we will explain how

**Abbas Zaidi** MBBS MRCP FRCP<sup>Path</sup> is a research fellow in Haematology at Barts Health NHS Trust, UK. Conflicts of interest: none.

**Laura Green** MBBS MD (Res) FRCP FRCP<sup>Path</sup> is a Consultant in Haemostasis and Transfusion Medicine at Barts Health NHS Trust and NHS Blood and Transplant, UK. Conflicts of interest: none.

## Learning objectives

After reading this article, you should be able to:

- identify the key components of haemostasis
- describe the principles of how some major inherited bleeding disorders impact haemostasis
- interpret abnormal coagulation assays
- describe how antiplatelets and anticoagulants affect coagulation

antiplatelets and antithrombotic drugs work, and also provide a basic understanding of how to interpret clotting tests used to measure coagulation disorders.

## Haemostasis

### Blood vessels and endothelial cells

Following vascular injury, vessel walls vasoconstrict immediately to slow blood flow to the site of injury as well as prevent exsanguination from widespread damage.<sup>1</sup> In addition, collagen and tissue factor (TF) are brought into contact with flowing blood. Exposed collagen triggers the accumulation and activation of platelets at the site of the vessel wall damage resulting in the formation of a platelet plug, while the exposed TF initiates the activation of coagulation factors and generation of thrombin which in turn will lead to formation and stabilization of insoluble fibrin clot.

### Platelet structure and function

Platelets are anucleate, extremely small, discoid cells which circulate in abundant numbers in the peripheral blood. They are formed by fragmentation from megakaryocytes within the bone marrow and have a lifespan of 7–10 days. Platelets are essential in the initial formation of a mechanical plug in response to vessel injury and they achieve this through four main functions: (1) activation; (2) adhesion to the vessel wall; (3) aggregation; and (4) secretion. Activated platelets provide a surface for activation and recruitment of more platelets, as well as activation of coagulation factors, which will ultimately lead to fibrin formation.

**Platelet membrane:** the platelet membrane invaginates into the interior of the cell and forms an extensive canalicular system, which provides a large area of numerous membrane receptors and proteins. Of particular importance in the platelet membrane are phospholipids which activate coagulation factors such as factor X (FX) and factor II (prothrombin). Surface receptors activate intracellular pathways which lead to a conformational change in platelet structure and shape upon activation. The membrane also contains numerous glycoproteins which serve as binding sites for various other molecules such as von Willebrand factor (vWF), fibrinogen (adhesion) as well as binding to other platelets (aggregation). [Table 1](#) summarizes the roles and clinical significance of some of the platelet membrane proteins.<sup>2</sup>

### Role and clinical significance of key platelet membrane proteins

Membrane Protein	Role	Clinical significance
GP1a	Binds collagen Activated intracellular pathways leading to thromboxane A2 (TXA2) generation	Aspirin suppresses TXA2 synthesis by inhibiting COX
GP1b	Binds von Willebrand factor	Defective in Bernard Soulier disease – results in bleeding disorders
GPVI	Binds collagen	GP VI Absence results in severe bleeding diathesis
GPIIb/IIIa	Binds fibrinogen and von Willebrand factor Binding site for other platelets in aggregation	Defective in Glanzmann's thrombaesthesia – results in bleeding disorders
Membrane phospholipid P2Y12	Activates coagulation factors Activated by ADP, leads to generation of TXA2 and aggregation	Activates factor X → Xa and factor II → IIa P2Y12 Inhibited by clopidogrel and ticagrelor

Key: GP, glycoprotein; TXA2, thromboxane A2; COX, cyclooxygenase; ADP, adenosine triphosphate; P2Y12, platelet membrane protein receptor.

**Table 1**

**Storage granules:** two important intracellular components within platelets are alpha and dense storage granules:

- $\alpha$  granules-contain P-selectin, fibrinogen, fibronectin, factor V, factor VIII, platelet factor IV, platelet-derived growth factor and tumour growth factor- $\alpha$  (TGF- $\alpha$ )
- dense granules-contain adenosine triphosphate (ATP), adenosine diphosphate (ADP), calcium (Ca), serotonin, histamine and epinephrine.<sup>3</sup>

**Platelet activation:** there are numerous agonists of platelet activation such as ADP, collagen serotonin – all these lead to activation of intracellular pathways. Collagen a potent activator of platelets, is released from vessel endothelium and binds to glycoprotein (GP) 1a and GPVI, which activates the cyclooxygenase (COX) system that will generate thromboxane A2 (TXA2). TXA2 has several haemostatic functions, such as: it causes vasoconstriction, it leads to recruitment and further activation of more platelets via thromboxane surface membrane

receptors, and also causes platelet aggregation. Aspirin inhibits TXA2 production by irreversible inhibition of COX enzyme (Table 2).

**Platelet adhesion:** upon activation, platelets undergo considerable conformational change in order to maximize surface area for adhesion to other surfaces. vWF is essential in promoting platelet adhesion in high shear conditions. vWF is released from the vascular endothelium where it is continually secreted and is stored within platelet granules and in Weibel-Palade bodies within endothelial cells. vWF is a large multimeric molecule that is essential in platelet adhesion, aggregation, and also act as a carrier for coagulation FVIII. Dysfunction or deficiency of vWF results in a bleeding diathesis. Shear forces, stress, exercise, adrenaline and desmopressin/DDAVP stimulates the release of vWF and thus will raise its plasma levels. DDAVP has therapeutic benefit in functional platelet disorders and in von Willebrand disease.

### Summary of antiplatelet drugs, mechanism of action and their limitations

Drug	Target	Binding	Route	Half Life
Aspirin	Acetylates Ser529 of COX-1	Irreversible	PO	15–20 minutes
Ticlopidine	ADP-P2Y <sub>12</sub>	Irreversible	PO	20–50hours after a single dose
Clopidogrel	ADP P2Y <sub>12</sub>	Irreversible	PO	7–8 hours
Prasugrel	ADP P2Y <sub>12</sub>	Irreversible	PO	7 hours
Cangrelor	ADP P2Y <sub>12</sub>	Reversible	IV	3–5 minutes
Ticagrelor	ADP P2Y <sub>12</sub>	Reversible	PO	7 hours (ticagrelor) 9 hours (active metabolite)
Abciximab	GP IIb/IIIa	Irreversible	IV	10–30 minutes
Tirofiban	GP IIb/IIIa	Reversible	IV	1.5–3 hours
Eptifibatide	GP IIb/IIIa	Reversible	IV	2–3 hours

PO, oral administration; IV, intravenous.

Adapted from Kottke-Marchat K, Davis B. Anticoagulant, antiplatelet and thrombolytic drugs, Chapter 41 in Laboratory Hematology Practice, Wiley–Blackwell 2012.<sup>8</sup>

**Table 2**

**Platelet aggregation:** platelet aggregation is achieved by platelets cross linking at GPIIb/IIIa receptors on the platelet membrane. GPIIb/IIIa is the most abundant glycoprotein, and upon activation it undergoes conformational change allowing it to bind to fibrinogen, thus forming platelet-fibrinogen bridges. ADP, TXA1 and thrombin all activate GPIIb/IIIa and are potent enhancers of platelet aggregation.

**Platelet secretion:** once activated, platelets release procoagulant substances that are responsible for a 'secondary wave' of aggregation after the initial activation of platelets. The two most significant substances responsible for this positive feedback are ADP (released from dense granules), and TXA2 generated from COX pathway. Other substances released from granules include serotonin, fibrinogen, fibronectin, and growth factors such as PDGF. Impaired release of these mediators results in qualitative defects of platelet function which can be both congenital or acquired (e.g. drug induced). Antiplatelet therapies target various pathways of platelet activation and aggregation - their target, route of administration and their half-lives are described in Table 2.

After activation, aggregation and secretion, the membrane phospholipid becomes exposed resulting in activation of the clotting cascade. Platelet phospholipids are essential for activation of FX and FII (thrombin) and the formation of the *tenase* (factors Xa-VIIIa- IXa) and *prothrombinase* complexes (factors Xa-Va-IIa).

### Coagulation pathway

The coagulation cascade involves the marked amplification of procoagulant proteins from relatively few initiation substances by the sequential activation of enzyme precursors (zymogens) to active enzymes. These are usually serine protease enzymes. The result is the rapid and marked generation of thrombin, which converts soluble fibrinogen into the insoluble fibrin. Fibrin enmeshes platelet aggregates and converts the unstable platelet plug into a stable fibrin clot.

Traditionally, the coagulation pathway was classified into extrinsic, intrinsic and common pathways. This classical model still remains useful in interpreting in vitro coagulation screening tests (i.e. prothrombin time [PT], activated partial thromboplastin time [APTT]); however, the classical model does not incorporate the central role that cell surfaces play in coagulation. Further, this system does not explain why some patients with coagulation factor deficiencies have bleeding tendencies (e.g. why individuals with factor IX or factor VIII deficiency have severe bleeding even though their extrinsic and common pathways are normal which should be sufficient for haemostasis), and more importantly, it does not predict which patients are at risk of bleeding or thrombosis.

### The cell-based model of haemostasis

The 'cell-based' model of haemostasis has replaced the classical pathway and it is now the most widely accepted model of in vivo coagulation. The cell-based model proposes that the coagulation process takes place on different cell surfaces and, occurs not as a cascade but in three overlapping stages which include initiation, amplification and propagation.<sup>4,5</sup>

**Initiation:** the primary event of in vivo coagulation is the exposure of tissue factor (TF) which will lead to activation of FVII in flowing blood after vascular injury. The TF:FVIIa complex catalyses the activation of FIX and FX. The activated FX which escapes the cell surface environment is rapidly inhibited by tissue factor pathway inhibitor (TFPI) and antithrombin (AT), whereas that which remains on the TF bearing cell will activate a tiny amount of thrombin from prothrombin. This initial thrombin is essential for the activation of more platelets, as well as activation of FVIII and FV, thus setting the scene for the large-scale thrombin generation. The small initial thrombin generated will also activate FXI in a positive feedback manner, leading to amplification.

**Amplification:** platelets provide the surface on which the amplification and propagation phases take place. During the amplification phase the procoagulant signal shifts from TF-bearing cells to the surface of platelets as these become activated, whilst in the propagation phase, a large burst of thrombin is generated on the surface of activated platelets (Figure 1).

The interaction of platelet GPVI receptor with exposed collagen from the vessel wall damage and platelet GP Ib-V-IX receptor with collagen-bound von Willebrand factor (vWF) promotes adhesion of platelets to the site of injury. These binding processes partially activate platelets and localize them near the site of TF exposure. Moreover, binding of vWF to GP-Ib-V-IX receptor<sup>5</sup> localizes FVIII to the surface of platelets where its activation will support the thrombin generation process.

Independently, the small amount of thrombin formed during the initiation phase enhances platelet adhesion and fully activates platelets as well as FV, FVIII and FXI. Thrombin induces platelet activation by binding to protease-activated-receptor 4 (PAR4) on the platelet surface which in turn causes the release of adenosine diphosphate, serotonin and thromboxane A2 from platelets. These agonists activate other platelets and in so doing they release FV from  $\alpha$  granules. FV is then fully activated by thrombin or FXa.

**Propagation:** during the propagation phase, FVIIIa combines with FIXa (generated by TF:VIIa complexes) to form the intrinsic 'tenase' complexes on the surface of activated platelets. This complex (FVIIIa/FIXa) is a powerful and a major activator of FX (ten fold more active than FIXa alone). FXa in combination with its co-factor FVa (and calcium ions) forms 'prothrombinase' complexes which will subsequently catalyse prothrombin to thrombin. This complex is 300,000-fold more active than FXa alone in catalysing prothrombin activation.

### Coagulation inhibitors

It is fundamental that clot formation is regulated and localized to the site of injury, so that arterial or venous thrombosis are prevented. Hence, a crucial element to a balanced haemostasis is played by the naturally occurring inhibitors to coagulation, which include *tissue factor pathway inhibitor* (TFPI), heparin co-factor II, antithrombin (AT), and protein C and protein S activation.

TFPI is the principle regulator of the thrombin generation initiation phase (i.e. inhibits FXa, FVIIa and TF), whereas AT attenuates thrombin activity and its generation (inhibits FIIa,




Figure 1

FXa, FIXa, and FXIa). TFPI is synthesized in endothelial cells and is mostly stored in platelets. A small amount is in free circulation in the plasma. Plasma concentrations of TFPI are greatly increased with heparin. Heparins bind to antithrombin and potentiate its action by 1000- to 4000-fold.

*Protein C and protein S* are both serine protease enzymes, whose activation is essential for inhibition of FVa and FVIIIa. The protein C/S pathway is activated by thrombin which binds to thrombomodulin (an endothelial cell surface receptor), and activate protein C – this in turn will inactivate FVa and FVIIIa. Protein S is a cofactor to activated protein C (APC), potentiating its action.

Almost all currently available anticoagulant drugs will inhibit either FXa or FIIa (thrombin) – Figure 1 gives an overview of the cell based model of haemostasis and the common targets of anticoagulant agents.

### Fibrinolysis

Following haemostasis, in order for vessel patency and blood flow to resume, the fibrin clot must be removed by proteolytic enzymes. Fibrinolysis is triggered in response to vessel injury, and requires activation of plasminogen to plasmin by the tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA).

t-PA is stored in the endothelium and is released following endothelial damage or stimulation by thrombin or vasoactive agents (adrenaline, bradykinin etc.). Fibrin acts as a cofactor for

t-PA to enhance the activation of plasminogen. Both t-PA and u-PA are used in clinical practice for thrombolysis – t-PA has been manufactured in recombinant form and urokinase isolated from human urine. Streptokinase is a peptide isolated from haemolytic streptococci which converts plasminogen to plasmin.

The main regulators of fibrinolytic systems are plasminogen activator inhibitor-1 (PAI-1), which targets u-PA and t-PA, and  $\alpha$ 2-antiplasmin that targets plasmin. Deficiencies of PAI or alpha-2-antiplasmin are rare disorders which result in a severe bleeding diathesis due to uninhibited fibrinolysis.

The antifibrinolytic drug tranexamic acid is a synthetic analog of lysine, which reversibly binds to plasminogen and prevents its activation to plasmin. This therefore prevents plasmin from degrading fibrin.

### Standard clotting tests and their interpretation

The most commonly used clotting assays include prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and Clauss fibrinogen assay. All these tests have limitations in that they are performed in plasma, and thus they do not reflect the *in vivo* haemostasis. As such, it is important to emphasize that when interpreting their results, the assessment of patient's bleeding history (i.e. current bleeding symptoms, prior bleeding events in responses to haemostatic challenges, such as surgery or dental extraction), drug history

### Screening tests of coagulation and their clinical implication

Test	Principle	Clinical Implication
APTT	Measure of intrinsic pathway coagulation factors	<p><i>Isolated prolonged APTT:</i>            Deficiency of FXII, XI, IX, VIII            Lupus anticoagulant antibodies            Antibodies to FVIII or FIX (i.e. acquired haemophilia)</p> <p><i>Prolonged APTT + PT:</i>            Vitamin K antagonists (e.g. warfarin)            Disseminated intravascular coagulopathy (DIC)            Common pathway deficiency            Afibrinogenaemia and dysfibrinogenemia            Direct thrombin inhibitors            Malabsorption (leading to vitamin K deficiency)            High concentrations of unfractionated heparin            Dilutional coagulopathy e.g. massive blood transfusion</p>
PT	Measures extrinsic and common pathway activity	<p>Isolated prolonged PT            Deficiency of factor VII</p>
Thrombin Time	Time to fibrin clot after addition of thrombin	<p>Prolonged thrombin time            Hypofibrinogenaemia — e.g. acquired from DIC, malignancy            liver disease            Following thrombolysis            Congenital deficiencies of fibrinogen            Direct thrombin inhibitors (eg dabigatran)</p>
Fibrinogen	Assay can be functional or quantitative	<p>Reduced            DIC            Liver disease            Inherited deficiency of fibrinogen            Thrombolysis            Increased            Pregnancy            Female sex            Acute phase response,</p>

Key: PT, Prothrombin time; APTT, a Activated partial thromboplastin time; DIC, d Disseminated intravascular coagulopathy.

**Table 3**

(use of anticoagulant/antiplatelet drugs), and family history of bleeding disorder must be taken into account.

**Prothrombin time:** the PT measures the time taken for clot formation when TF (thromboplastin) and calcium are added to platelet depleted plasma. There are several thromboplastin reagents commercially available, and each of them have a variable sensitivity. Hence, in order to standardize the PT assay, individual thromboplastin reagents are compared with a World Health Organization standard reference and assigned an ISI (International Standardized Index). The ISI of each PT reagent is then used to calculate the international normalized ratio (INR — see formula below), which is essential for determining the anti-coagulant status of patients taking vitamin K antagonist agents (such as warfarin).

INR is calculated from the following formula:

$$\text{INR} = [\text{Test PT} \div \text{Reference PT (mean of 20 normal donors)}]^{1.51}$$

PT measures the activity of extrinsic and common pathway, and therefore will be affected by plasma concentration of FVII, FV, FX, FII (prothrombin) and fibrinogen.

**Activated partial thromboplastin time:** the APTT Measures the activity of the intrinsic pathway, thus it will be affected by abnormalities of factors XII, XI, VIII, IX as well as the common pathway factors V, X, II (prothrombin) and fibrinogen.

APTT measures the time taken for clot formation in platelet poor plasma after the addition of phospholipid (partial thromboplastin), a contact activator (a negatively charged substance that will activate the contact system) and calcium. It is important to note that deficiency of FXII (or contact factor) will cause marked prolongation of the APTT, but this condition does not carry any bleeding risk.

Another common pitfall to be aware of when APPTT is prolonged, are the lupus anticoagulant antibodies, which are inhibitory antibodies associated with the antiphospholipid syndrome

### Summary of anticoagulant drugs, their mechanism of action, effect on coagulation tests and haemostatic measures to consider in management of major bleeding

Anticoagulant Class	Examples	Route	Half-life	Mechanism of action	Effect on clotting Tests	Specific assays	Reversal agents to consider in major bleeding
Vitamin K antagonist (VKAs)	Warfarin Sinthrome Coumadin	PO	40–70 h	Vitamin K epoxide reductase inhibition – factors II, VII, IX, X, protein C, S, Z	<b>PT</b> ↑↑↑ APTT ↑↑ Fib ↔ TT ↔/↑	INR	Vitamin K Prothrombin Complex Concentrate (PCC)
Unfractionated heparin	Unfractionated heparin	IV	30 mins–4 h	Potentialiation of antithrombin – targets IIa, Xa, IXa, XIa	PT ↔/↑ <b>APTT</b> ↑↑↑ Fib ↔ TT ↔/↑	APTT ratio	Protamine
Low molecular weight Heparin	Enoxaparin Dalteparin Tinzaparin	SC SC SC	3–6 h	Potentialiation of antithrombin – targets Xa, IIa, tissue factor pathway inhibitor	PT ↔/↑ <b>APTT</b> ↑↑ Fib ↔ TT ↔/↑	*Anti Xa Level using respective LMWH	Consider Protamine if <16 hr of administration
Indirect Xa inhibitor	Fondaparinux	SC	17–20 h	Target Xa inhibition, through potentialiation of antithrombin	<b>PT</b> ↔/↑↑ APTT ↔/↑ Fib ↔ TT ↔	*Anti Xa Level using fondaparinux	No antidote Consider Tranexamic acid + PCC in severe bleeding
Direct Xa inhibitors	Apixaban Rivaroxaban Edoxaban	PO BD PO OD PO OD	8–15 h 5–13 h 10–14 h	Direct Xa inhibition	<b>PT</b> ↔/↑↑ APTT ↔/↑ Fib ↔ TT ↔	*Anti Xa Level using respective drugs	No reversal agent yet available (Andexanat Alpha awaiting licence)  Tranexamic acid Consider PCC in severe bleeding
Direct thrombin inhibitors	Dabigatran Argatroban Bivalirudin Hirudin	PO BD IV IV	12–17 h 45 min 25 min 1–2 h	Direct thrombin inhibition	PT ↑/APTT ↑↑ Fib ↑ <b>TT</b> ↑↑↑↑↑	*Haemoclot Assay or dilute thrombin time	Idaricizumab if available No antidote for parenteral Direct Thrombin inhibitors

\*Monitoring not required. The effect of anticoagulants may cause prolongation of a single or multiple clotting tests but can do so to a varying degree or not at all. Clotting tests highlighted in bold show the clotting test that would be expected to be most significantly prolonged due to the anticoagulant.

Key: ↑, prolongation (quantitative); ↑↑, moderate prolongation; ↑↑↑, marked prolongation; ↔, unchanged. LMWH, low molecular weight heparin; PT, prothrombin time; APTT, activated partial thromboplastin time; Fib, fibrinogen; TT, thrombin time; INR, international normalized ratio.

**Table 4**

(rarely can affect the PT). Lupus anticoagulant antibodies are associated with thrombotic tendency rather than bleeding risk.<sup>6,7</sup>

**Thrombin time:** The thrombin time assesses the conversion of fibrinogen to fibrin and is measured simply by adding exogenous thrombin to platelet depleted plasma.

**Fibrinogen levels** are a useful part of the investigation of prolonged APTT or PT. There are different methods of assaying fibrinogen – the two commonest methods are either Clauss Fibrinogen – a functional assay based on the time for a fibrin clot formation and the PT derived fibrinogen – where fibrinogen level is derived based upon the prothrombin time.

Clinical interpretation of abnormal clotting tests are described in Table 3.

Table 4 provides a summary of anticoagulant drugs, their mechanism of action, effect on coagulation tests and haemostatic measures to consider in management of major bleeding. ◆

## REFERENCES

- 1 Furie B, Furie BC. Mechanisms of thrombus formation. *N Engl J Med* 2008; **359**: 938–49.
- 2 Ramalingam G, Jones N. Platelets for anaesthetists – Part 1: physiology and pathology. *Br J Anaesth Education* 2016; **16**: 134–9.
- 3 Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. *Thromb Haemostasis* 2002; **88**: 186–93.
- 4 Hoffman M, Monroe DM. A cell-based model of hemostasis. *Thromb Haemost* 2001; **85**: 958–65.
- 5 Monroe DM, Hoffman M, Roberts HR. Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. *Blood Coagul Fibrinolysis* 1996; **1996**: 459–64.
- 6 Practical haemostasis website - [www.Practicalhaemostasis.com](http://www.Practicalhaemostasis.com).
- 7 Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology -. *Br J Haematol* 2012; **159**: 427–9.
- 8 Kottke-Marchat K, Davis B, eds. Anticoagulant, antiplatelet and thrombolytic drugs, Chapter 41 in *Laboratory Haematology Practice*. Wiley-Blackwell, 2012.

## FURTHER READING

- Hoffbrand AV. *Essential haematology*. 6<sup>th</sup> Edn. Wiley Blackwell, 2011.
- Hoffbrand AV. *Postgraduate haematology*. 7<sup>th</sup> Edn. Wiley Blackwell, 2016.